Immune Clinical Trials in Tianjin, Tianjin Municipality
30 recruitingTianjin, Tianjin Municipality, China
Showing 1–20 of 30 trials
Recruiting
Phase 3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Takeda171 enrolled112 locationsNCT06722235
Recruiting
Phase 3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Takeda150 enrolled108 locationsNCT06948318
Recruiting
Phase 2
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
Lung CancerRadiotherapyImmune Checkpoint Inhibitor+1 more
Tianjin Medical University Cancer Institute and Hospital30 enrolled3 locationsNCT07058948
Recruiting
Early Phase 1
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)Autoimmune Hemolytic Anemia, AIHA+1 more
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Phase 1
Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
Primary Immune Thrombocytopenia (ITP)
Chongqing Peg-Bio Biopharm Co., Ltd.12 enrolled5 locationsNCT06880081
Recruiting
National Longitudinal Cohort of Hematological Diseases
Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome+14 more
Institute of Hematology & Blood Diseases Hospital, China2,300 enrolled1 locationNCT04645199
Recruiting
Phase 2
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07362199
Recruiting
Early Phase 1
CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases
Autoimmune Diseases
Institute of Hematology & Blood Diseases Hospital, China15 enrolled1 locationNCT06680388
Recruiting
Phase 2
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China60 enrolled1 locationNCT06168851
Recruiting
Phase 1Phase 2
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06776510
Recruiting
Phase 2
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT07063199
Recruiting
National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia
AIHA - Warm Autoimmune Hemolytic AnemiaAIHA - Cold Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Anemia Mixed Type
Institute of Hematology & Blood Diseases Hospital, China9,999 enrolled1 locationNCT07019038
Recruiting
Phase 1Phase 2
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
Chronic Immune Thrombocytopenia
CASI Pharmaceuticals, Inc.75 enrolled6 locationsNCT07017725
Recruiting
Phase 2
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China129 enrolled1 locationNCT06992128
Recruiting
Phase 3
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
Primary immune thrombocytopenia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.199 enrolled53 locationsNCT06900920
Recruiting
Phase 2
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
TreatmentImmune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06799611
Recruiting
Phase 2
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT05214391
Recruiting
Not Applicable
TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years
Primary Immune Thrombocytopenic Purpura
Institute of Hematology & Blood Diseases Hospital, China100 enrolled1 locationNCT04890041
Recruiting
Phase 1
CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.
Autoimmune Hemolytic AnemiaCD19/BCMA CAR T-cellsUniversal Allogeneic CAR T-cells
Institute of Hematology & Blood Diseases Hospital, China15 enrolled1 locationNCT06733610
Recruiting
Not Applicable
The Effect of Serum Ferritin in irAE
Acute LeukemiaMalignant Solid TumorsImmune-related Adverse Event+1 more
Tianjin Medical University Cancer Institute and Hospital1,500 enrolled1 locationNCT06702566